Ingevity Corp. Files 8-K: Material Agreement & Financial Obligation

Ticker: NGVT · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001653477

Ingevity Corp 8-K Filing Summary
FieldDetail
CompanyIngevity Corp (NGVT)
Form Type8-K
Filed DateMar 30, 2026
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $1 billion, $750 million, $512.1 million
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, financial-obligation, 8-k

TL;DR

Ingevity signed a big deal, now has new financial obligations. Details in 8-K.

AI Summary

On March 26, 2026, Ingevity Corp. entered into a material definitive agreement, as detailed in Item 1.01 of their 8-K filing. This agreement also created a direct financial obligation for the registrant, as noted in Item 2.03. The filing includes financial statements and exhibits as per Item 9.01.

Why It Matters

This filing indicates Ingevity Corp. has entered into a significant new agreement that likely involves financial commitments, potentially impacting its future financial performance and operations.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements and creating new financial obligations can introduce financial risks and operational changes that may affect the company's performance.

Key Players & Entities

FAQ

What type of material definitive agreement did Ingevity Corp. enter into?

The filing indicates Ingevity Corp. entered into a material definitive agreement, but the specific details of the agreement are not provided in the summary information. The full text of Exhibit 10.1 would contain these details.

What is the nature of the direct financial obligation created for Ingevity Corp.?

The 8-K filing states that a direct financial obligation was created under Item 2.03, but the specific terms and amount of this obligation are not detailed in the provided summary. Exhibit 10.1 would likely contain this information.

When was this 8-K filing accepted by the SEC?

The 8-K filing was accepted by the SEC on March 30, 2026, at 06:30:49.

What are the main items reported in this 8-K filing?

This 8-K filing reports on Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant), and Item 9.01 (Financial Statements and Exhibits).

Where is Ingevity Corp. headquartered?

Ingevity Corp.'s mailing and business address is listed as 4920 O'HEAR AVENUE SUITE 400 NORTH CHARLESTON SC 29405.

Filing Stats: 808 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2026-03-30 06:30:49

Key Financial Figures

Filing Documents

01. ENTRY INTO

Item 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On March 26, 2026 (the " Closing Date "), Ingevity Corporation (the " Company "), Ingevity Holdings SRL (" Holdings "), Ingevity UK Ltd (the " UK Borrower "), the other loan parties party thereto, the lenders party thereto, the issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the " Administrative Agent "), collateral agent and swingline lender, entered into that certain Second Amendment and Restatement Agreement (the " Amendment "), which amends and restates the Amended and Restated Credit Agreement, dated as of June 23, 2022 (the " Existing Credit Agreement ," and as amended and restated by the Amendment, the " Second Amended and Restated Credit Agreement "), by and among the Company, Holdings, the UK Borrower, the lenders from time to time party thereto and the Administrative Agent. The Amendment amends and restates the Existing Credit Agreement to, among other things, (a) extend the maturity date of the Company's revolving credit facility to the date that is five years after the Closing Date, (b) decrease the aggregate amount of the commitments thereunder from $1 billion to $750 million and (c) effect certain other amendments. Borrowings under the revolving credit facility bear interest at a rate per annum equal to, at the Company's option, either (a) the applicable term benchmark rate, subject to a 0.00% floor, or (b) a base rate, in each case, plus an applicable margin of 1.00% to 1.75% for term benchmark loans and 0.00% to 0.75% for base rate loans. The Second Amended and Restated Credit Agreement contains certain customary affirmative and negative covenants, representations and warranties and events of default (subject in certain cases to customary grace and cure periods). On the Closing Date, the Company repaid all of its outstanding revolving loans in an aggregate principal amount of $512.1 million. The foregoing summary of the Amendment does not purport to be comp

03. Creation of

Item 2.03. Creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant The information in Item 1.01 above is incorporated by reference into this Item 2.03.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Second Amendment and Restatement Agreement, dated as of March 26, 2026, among Ingevity Corporation, Ingevity Holdings SRL, Ingevity UK Ltd, the other loan parties party thereto, JPMorgan Chase Bank, N.A., as the administrative agent, and the lenders party thereto 104 Cover Page Interactive Dat a File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INGEVITY CORPORATION (Registrant) By: /s/ Mary Dean Hall Mary Dean Hall Executive Vice President and Chief Financial Officer Date: March 30, 2026

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing